Innovation at the Cellular Level
Based in Reutlingen, Germany, TETEC has over 20 years of experience in developing innovative cell-based therapies for cartilage regeneration. We offer two matrix-associated autologous chondrocyte transplantation (MACT) procedures: Injectable MACT and Scaffold-Based MACT. Together, these two treatment procedures have been used to treat more than 30,000 patients to date [1].
As part of the Octane Medical Group, a global organization focused on bioprocess development and automation, we continue to advance manufacturing processes and biomaterials for the next generation of cartilage regeneration.
Source: TETEC AG
Setting a New Standard
Today, the manufacture of autologous matrix-associated chondrocyte transplants remains a complex process with demanding requirements for logistics, infrastructure, and quality assurance.
Together with Octane, we are working to reimagine this process. We are developing automated cell manufacturing technologies that could enable production closer to the patient while maintaining consistently high quality standards. Our goal is to make regenerative therapies more accessible and easier to integrate into routine clinical practice. Ultimately, we aim to help establish regenerative medicine as the new standard of care.
Powering Tomorrow's Care
Innovative technologies such as the Octane Cocoon® bioreactor play a central role in our vision. This closed, automated system enables cell therapies to be produced under GMP conditions and could help bring manufacturing closer to the point of care. Learn more about Cocoon® and its potential to support the next generation of cartilage regeneration.
Cell-Based Cartilage Regeneration for the Knee
TETEC offers two cell-based treatment procedures for cartilage regeneration: Injectable MACT and Scaffold-Based MACT.
Injectable MACT
Injectable MACT is a cell-based procedure for the treatment of focal cartilage defects of the knee. The procedure uses a patient's own cartilage cells in combination with an injectable hydrogel for transplantation into the cartilage defect [2]. In clinical studies and earlier publications, this procedure has also been referred to as hydrogel-based ACI or Injectable M-ACI.
- A patient's own cartilage cells suspended in an injectable hydrogel
- Minimally invasive arthroscopic transplantation
- May be performed on an inpatient or outpatient basis, depending on the indication
.avif)
Scaffold-Based MACT
In Scaffold-Based MACT, a patient's own cartilage cells are seeded onto a collagen scaffold and transplanted into the cartilage defect [3].
- Collagen-based scaffold seeded with a patient's own cartilage cells
- Transplantation via a small surgical approach (mini-arthrotomy)
- May be performed on an inpatient or outpatient basis, depending on the indication
From Discovery to Therapy
TETEC combines expertise in cell biology, biomedical engineering, materials science, and orthopaedics. In collaboration with academic, clinical, and industrial partners, we investigate and develop new biomaterials, optimize cell culture processes, and translate scientific discoveries into innovative therapies while adhering to the highest standards of safety, quality, and regulatory compliance in accordance with Good Manufacturing Practice (GMP).
Our Leadership
Our leadership team brings together decades of experience across the full value chain of innovative therapies, from research and development through manufacturing to commercialization.
Our Network
TETEC collaborates with leading academic, clinical, and industrial partners to advance research and therapeutic development in regenerative medicine.
Scientific Recognition
TETEC Locations
Our sites in Germany, Canada, and the United States provide the infrastructure and manufacturing capacity needed to reliably serve existing markets while supporting future growth.
Where Innovation Meets Quality
Our Reutlingen site, located near Stuttgart Airport, is equipped with modern cleanroom facilities and specialized laboratory infrastructure for cell culture and tissue engineering. Together with Octane, we are developing Reutlingen into a centre of excellence for cartilage regeneration with capacity to support future growth. Learn more about our facility and the quality and manufacturing standards in place to ensure safe, consistent, and regulatory-compliant production.
Regulatory Standards and Compliance
Cell therapies are manufactured under strict European regulatory standards to ensure the highest levels of safety, quality, and traceability.
Join Our Growing Team
Help shape the future of regenerative medicine. Our team of more than 140 professionals brings together expertise in cell and molecular biology, medicine, and pharmacology. Whether in quality control, manufacturing, logistics, or research, you will find opportunities for professional development in an environment that fosters individual potential and supports both professional and personal growth. Together, we develop innovative therapies designed to improve the health and quality of life of patients.
.avif)
%201.png)
"I value taking on responsibility and actively driving change. Working together with the different teams makes this role especially exciting.”
Larissa Bocks
Director HR & Business Operations
"I am motivated by improving processes and tackling challenges within interdisciplinary teams. As a relatively small and diverse company with flat hierarchies, decision-making processes can be carried out quickly.”
Katharina Reinhardt Heller
Vice President Manufacturing Operations
"TETEC AG is also a wonderful employer for career starters, offering a great first step from the university environment into industry. The helpfulness of the colleagues turns an applicant into a fully valued team member.”
Raphael Parusel
Team Lead Supply Chain Management, Supplier Quality
2025-01-02
TETEC AG’S CDMO business is now Octane CDMO, a global operation with automation expertise
Kingston, Ontario, January 2, 2025 – The Octane Medical Group is pleased to announce that the contract development and manufacturing arm of its German subsidiary TETEC AG...
2024-06-11
Octane Medical acquires B. Braun’s global orthobiologics business
Kingston, Ontario, Canada / Melsungen, Germany, June 5th, 2024 – Octane Medical Group...
2023-12-18
Application for central authorisation submitted to the EMA
TETEC AG has submitted an application for centralized approval of a gel-based matrix-associated cartilage cell product as an advanced...
Connect with TETEC
Conferences
Connect with TETEC at upcoming MACT congresses and events
03.-05.12.26
TIRM Regensburg "Osteotomy Plus Around the Knee"
05.12.2026
Sporttraumatologisches Symposium Sportheum Sportklinik Fellbach
13./14.11.26
QKG Basis- u. Spezialkurs Essen
15./16.10.26
6. Berliner Traumakurs am Unfallkrankenhaus
17.-19.09.26
43. AGA Jahreskongress Innsbruck
20./21.11.26
Update Neuss
27./28.11.26
15. Jahreskongress d. Dt. Kniegesellschaft München
Keep Exploring
Learn more about our treatment options for cartilage defects. Our information for patients and healthcare professionals helps you quickly find the content most relevant to your needs.
1. Data on file. TETEC AG. Internal registry and internal documentation of Injectable MACT and Scaffold-Based MACT procedures performed in Germany. Reutlingen (DE): TETEC AG; 2025.
2. TETEC AG. Summary of Product Characteristics (SmPC) NOVOCART® Inject. Reutlingen (DE): TETEC AG; 2026. Revision date: 02/2026. PEI.A.11763.01.1.
3. TETEC AG. Summary of Product Characteristics (SmPC) NOVOCART® 3D. Reutlingen (DE): TETEC AG; 2023. Revision date: 11/2023. PEI.A.11511.01.1.